You Searched For "GlaxoSmithKline" and got 20 results
Sort By:
1 min read
Glenmark gets USFDA nod to market generic medication
The company's product is the generic version of GlaxoSmithKline's Compazine tablets, it added. …
PTI
2 mins read
GlaxoSmithKline is facing an uncertain vaccine future
These are Insider's biggest healthcare stories for April 13.
Lydia Ramsey Pflanzer
1 min read
GSK climbs 6% on report of Elliot Management's multibillion stake
Elliott enters the picture amid GSK's struggle to come back after falling behind in the COVID-19 va…
Isabelle Lee
1 min read
Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shot
The two vaccine-making giants plan to launch a 35,000-person study in the next few weeks, aiming to…
Andrew Dunn
4 mins read
The future of COVID-19 vaccines
These are Insider's biggest healthcare stories for the week ending April 16.
Lydia Ramsey Pflanzer
1 min read
Vir Biotechnology spikes 36% after it says its COVID-19 treatment reduced hospitalizations and deaths in high-risk patients
The company said it will seek emergency use authorization for the drug in the US and in other count…
Isabelle Lee
2 mins read
GSK and CureVac are making 'next-generation' vaccines that they say can tackle multiple COVID-19 variants at once
The new GSK-CureVac mRNA vaccines will target coronavirus variants and could be available in 2022, …
Dr. Catherine Schuster-Bruce
3 mins read
HUL shares are red hot as investors look past recent hiccups
The investors in India’s largest consumer staples company Hindustan Unilever (HUL) have recovered f…
3 mins read
GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.
The pharmaceutical giants GlaxoSmithKline and Sanofi said they'd improve their formulation and star…
Grace Dean
3 mins read
GSK merger became a pain killer for HUL
Revenue from every segment, except food and refreshment, took a beating as dem…
8 mins read
Even if a successful coronavirus vaccine is developed, billions could struggle to access it because of a global shortage of glass vials
Vaccines are stored in glass vials, which are running low, slow to produce, and invariably the main…
Bill Bostock
1 min read
Chandigarh NCLT nod for HUL, GlaxoSmithKline Consumer Healthcare merger deal
On December 3, 2018, Anglo-Dutch FMCG giant Unilever had announced the acquisition of health food …
PTI
1 min read
GlaxoSmithKline Pharma posts net loss of Rs 661.16 cr for Dec quarter
New Delhi, Feb 3 () Drug firm GlaxoSmithKline Pharmaceuticals on Monday reported a consolidated net…
PTI
5 mins read
2018 was a big year for mergers and acquisitions in India. Here are the top deals
This year proved to be quite a robust one for mergers and acquisitions for Indian corporates. Bu…
2 mins read
Hindustan Unilever and GlaxoSmithKline’s domestic consumer unit are merging in what is said to be India’s largest consumer goods deal ever
The businesses being divested, which include health drinks Horlicks, Maltova and Boost, brough…
2 mins read
Here’s why the Supreme Court has exempted Saridon from the ban on FDCs
A Supreme Court bench announced its decision while hearing a plea from drug manufacturers P…
3 mins read
The coronavirus vaccine from Sanofi and GlaxoSmithKline will receive up to $2.1 billion from Operation Warp Speed — here's how it compares to other candidates
Sanofi recently moved up the date of its first clinical trial to September. Companies like Moderna'…
Aria Bendix
2 mins read
Pharma giant GlaxoSmithKline signs mega deal with Pfizer that could change the face of global healthcare
"Ultimately, our goal is to create two exceptional, UK-based global companies, with appropriate cap…
Callum Burroughs
2 mins read
EXCLUSIVE: The Chief Digital Officer at GSK tells us how traditional FMCG companies are adapting to a digitally evolving consumer base
"We see Digital medium a catalyst for marketing transformation. It offers a huge opportunity …
4 mins read
A top exec at GlaxoSmithKline gave us an inside look at the $100 billion pharma giant's experiment with a new way of getting paid for medicines
The program tracks whether patients have used a rescue inhaler as a stand-in for how well medicatio…